The Australian biotech GPN Vaccines has expanded a partnership with compatriot contract development and manufacturing organization (CDMO) BioCina to scale up the manufacture of its lead candidate vaccine against pneumococcal diseases such as pneumonia,...
The UK has unveiled £34.5 million ($42.8 million) in funding for four hubs dedicated to the development of vaccines for diseases with epidemic potential in low- and middle-income countries (LMICs).
While the pandemic brought new entrants into the market, vaccine manufacturing remains a complex activity undertaken by a limited number of companies with the overall picture largely unchanged by COVID-19.
Cholera outbreak response campaigns should now use single-dose instead of two-dose vaccination campaigns, the WHO recommends, as it highlights global cholera vaccine shortages. It is calling on the world’s leading vaccine manufacturers to step up and...
The WHO has set out a new blueprint for dementia research: outlining the potential of precision medicine, repurposed drugs and revamped clinical trials. “Addressing dementia is one of the greatest health challenges of our generation,” says the organization.
The World Health Organization (WHO) has published its first guidelines for Ebola virus disease therapeutics, issuing ‘strong recommendations’ for the use of two monoclonal antibodies.
The WHO has updated its advice on COVID-19 booster doses: including recommendations on which groups should receive a second booster shot and how countries should plan around the upcoming availability of variant-specific vaccines.
Releasing its first-ever report on the pipeline of vaccines in development to prevent infections caused by antimicrobial-resistant (AMR) bacterial pathogens, the WHO is calling for more AMR vaccine development.
The World Health Organization (WHO) has today issued an emergency use listing (EUL) for Convidecia, a vaccine manufactured by CanSino Biologics, bringing the total number of COVID-19 vaccines validated by the organisation to 11.
A global biomanufacturing training hub will be established in Korea to serve low- and middle-income countries wishing to produce biologicals such as vaccines, insulin, monoclonal antibodies and cancer treatments.
Last week saw the WHO announce the first six countries that will receive the technology needed to produce mRNA vaccines on the African continent, as part of the global mRNA technology transfer hub project.
The COVID-19 pandemic has reversed years of global progress in tackling tuberculosis and - for the first time in over a decade - TB deaths have increased. Research breakthroughs – such as new vaccines – are needed to rapidly reduce the number of new cases...
The World Health Organization is recommending widespread use of the RTS,S/AS01 (RTS,S) vaccine among children in sub-Saharan Africa and other regions with moderate to high malaria transmission.
While several vaccines protect against meningitis, there remains an urgent need for innovation, funding and research to develop more meningitis-preventive vaccines, according to a new report from the WHO.
Johnson & Johnson says data published in The Lancet on its Ebola vaccine regimen shows it has a robust and durable immune response in adults and children.
The World Health Organization’s Solidarity PLUS trial will kick off in 52 countries, trialing three drugs to treat patients hospitalized with COVID-19.
WHO is recommending the use of interleukin-6 (IL)-6 receptor blockers in patients with severe and critical COVID-19, adding them to its list of treatments for the virus.
The World Health Organization (WHO) is assigning ‘simple, easy to say and remember’ labels to key variants of SARS-CoV-2, using letters of the Greek alphabet.
The World Health Organization (WHO) and the Swiss Confederation have launched the first WHO BioHub Facility to enhance the rapid sharing of viruses and other pathogens between laboratories and partners globally.
Convergence towards common global standards for clinical trial application (CTA) rules, along with unilateral and mutual recognition of CTA approvals are some suggestions made by industry insiders in a new paper to enable robust and timely development...
AstraZeneca’s COVID-19 vaccine has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO): meaning the vaccine can be rolled out globally through COVAX.
While some jurisdictions have limited the use of the Oxford University / AstraZeneca COVID-19 vaccine, the WHO says it can be used even where variants are known to be in circulation and with people aged 65+.
Advice published by the World Health Organization today says the two doses of the Moderna vaccine should be administered 28 days apart; but this interval can be extended up to 42 days if necessary.
The World Health Organization’s Global Advisory Committee on Vaccine Safety says it has not seen any unexpected or untoward increase in fatalities in frail and elderly individuals who have received the Pfizer/BioNTech vaccine.
The World Health Organization’s vaccine advisory group recommends the two doses of the Pfizer/BioNTech vaccine should be delivered 21 to 28 days apart: although it adds that the maximum time period between doses could be up to six weeks in some situations.
To support COVID-19 global preparedness, Stirling Ultracold is engaging directly with several pharmaceutical companies currently involved in COVID-19 vaccine development, with the idea of building a fleet of ULT freezers capable of storing their approved...
UNICEF, the world’s largest single buyer of vaccines, is laying the groundwork for quick and efficient delivery of COVID-19 vaccines by purchasing and distributing more than half a billion single-dose syringes and other critical equipment in countries...
The Alliance for Regenerative Medicine released a ‘Statement of Principles’ on gene editing, as controversy over the technology’s potential rumbles on.
Sanofi warns that the World Health Organization’s delayed strain selection will push back the date on which it delivers vaccines for the 2019-2020 flu season.
A prequalification pilot designed to assess biosimilar versions of Roche’s Rituxan and Herceptin has attracted global interest from manufacturers, says WHO executive.